By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

Illumina, Inc. 

9885 Towne Centre Drive

San Diego  California  92121-1975  U.S.A.
Phone: 858-202-4500 Fax: 858-202-4545


SEARCH JOBS
innovative technologies
At Illumina, our goal is to apply innovative technologies and revolutionary assays to the analysis of genetic variation and function, making studies possible that were not even imaginable just a few years ago. These studies will help make the realization of personalized medicine possible. With such rapid advances in technology taking place, it is mission critical to have solutions that are not only innovative, but flexible, scalable, and complete with industry-leading support and service. As a global company that places high value on collaborative interactions, rapid delivery of solutions, and prioritizing the needs of its customers, we strive to meet this challenge. Illumina’s innovative, array-based solutions for DNA, RNA, and protein analysis serve as tools for disease research, drug development, and the development of molecular tests in the clinic.

Leading-edge products and services
Illumina has developed a comprehensive line of products that address the scale of experimentation and the breadth of functional analysis required to achieve the goals of molecular medicine. Our offering includes leading-edge solutions for:

  • SNP genotyping
  • Copy number variation
  • DNA methylation studies
  • Gene expression profiling
  • Low-multiplex analysis of DNA, RNA, and protein

    Our products and services are used by a broad range of academic, government, pharmaceutical, biotechnology, and other leading institutions around the globe.

    a collaborative approach
    In concert with prospective customers and partners, Illumina takes a highly collaborative approach to business relationships. We're good listeners, value feedback, and believe in working together. Illumina is committed to providing our customers with world-class solutions, service, and support throughout their relationship with us to maximize their scientific success.

    Building the illumina community
    Staffed with a cohesive mix of high-performing scientists, engineers, managers, and support staff, Illumina is committed to building a team that delivers high-quality products and industry-leading service to the marketplace. Every employee is a critical part of the growing Illumina Community. Through our actions we strive to invite everyone associated with our company to become a part of this community. This includes customers, collaborators, suppliers, and industry colleagues.

    Key Management:
    Jay T. Flatley
    President & Chief Executive Officer

    Christian G. Cabou
    Senior Vice President & General Counsel

    Gregory F. Heath, Ph.D.
    Senior Vice President & General Manager, Diagnostics Business Unit

    Christian Henry
    Senior Vice President, Chief Financial Officer & General Manager, Life Sciences Business Unit

    Tristan B. Orpin
    Senior Vice President & Chief Commercial Officer

    Nicholas J. Naclerio, Ph.D.
    Senior Vice President, Corporate Development

    Mostafa Ronaghi, Ph.D.
    Senior Vice President & Chief Technology Officer

    Key Statistics


    Email: info@illumina.com
    Ownership: Public

    Web Site: Illumina
    Employees: 1200+
    Symbol: ILMN
     









  • Company News
    Illumina (ILMN) Launches iHope Program To Identify Causes Of Undiagnosed Genetic Diseases In Children 12/1/2016 7:55:51 AM
    Illumina (ILMN) And Mayo Clinic Form Bioinformatics Relationship To Advance Genetic Disorder Testing 11/10/2016 2:10:50 PM
    Illumina (ILMN) Plunges Into Its Own Next-Generation Journey 11/9/2016 7:16:08 AM
    How Illumina (ILMN) Stacks Up Against Warren Buffet's Acquisition Criteria 11/8/2016 6:46:30 AM
    Illumina (ILMN) Launches TruSight Tumor 170 11/7/2016 9:03:39 AM
    NRGene And Japan's Kazusa DNA Research Institute Fully Reveal The Complex Genome Of Strawberry Using Illumina (ILMN) Data 11/4/2016 11:42:30 AM
    Illumina (ILMN) Is Floundering: Here's What Management Had To Say 11/4/2016 6:55:29 AM
    Illumina (ILMN) Reports Full Financial Results For Third Quarter Of Fiscal Year 2016 11/2/2016 10:00:29 AM
    Illumina (ILMN) Release: German Court Issues Preliminary Injunction Against amedes Fetalis Test For Infringement Of Non-Invasive Prenatal Screening Patent 10/25/2016 11:57:30 AM
    Helmed by Affymetrix (Santa Clara, California) (AFFX)-Illumina (ILMN) Alum, Bay Area Startup Cirina Emerges With $12 Million to Develop Noninvasive Tests for Early Cancer Screening 10/25/2016 9:56:06 AM
    12345678910...
    //-->